ArticleMicrobial biotechnology2024
Akkermansia muciniphila outer membrane protein regulates recruitment of CD8
Article in Microbial biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Gut microbiota composition in responders vs. non-responders with hepatocellular carcinoma under ICI therapy: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- The role ofFrontiers in medicine · 2025Pooled it
- An engineered probiotic Escherichia coli Nissle 1917 strain for Amuc_1100 delivery in a CT26 colorectal tumor model.Probiotics and antimicrobial proteins · 2026Article
- The inhibition of lactate/Gpr81 signalling driven by moderate-intensity continuous training protects against osteoarthritis.Experimental & molecular medicine · 2026Article
- Akkermansia muciniphila : A next-generation gut probiotic supporting neurorepair and functional recovery.Neural regeneration research · 2026Article
- Decoding Akkermansia muciniphila Effector Biology: From Microbial Molecules to Host Outcomes.MicrobiologyOpen · 2026Review
- Multi-omics links microbial dysbiosis, systemic inflammation, and metabolomic disruptions to SNAE risk in treated HIV.JCI insight · 2026Article
- Icariin Enhances the Enzymatic Activity of N-acetylgalactosaminidase to Augment Akkermansia Abundance in Gut Microbiota for Improved PD-1 Blockade Efficacy in Tumor Suppression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Functional Proteins of Akkermansia Muciniphila: Impacts on Host Health and Metabolism.Probiotics and antimicrobial proteins · 2026Review
- Multi-omics links microbial dysbiosis, systemic inflammation and metabolomic disruptions to SNAE risk in treated HIV.bioRxiv : the preprint server for biology · 2026Article
- Insights into the Functions, Characteristics, and Mechanisms of Disease-Related Proteins fromMicroorganisms · 2026Review
- Modulatory role of Akkermansia muciniphila in cancer pathophysiology: a systematic review and meta-analysis of preclinical studies.Gut pathogens · 2026Review
- Multi-Omics Analysis Reveals the Potential Preventive Mechanism of Lactobacillus salivarius Li01 Against L-Arginine-Induced Acute Pancreatitis in Mice.Microbial biotechnology · 2026Article
- Gut microbial diversity and compositional shifts are associated with differential tumor growth rates in mice.BMC microbiology · 2025Article
- Unraveling the alterations and biomarkers in the tumor microenvironment in lung adenocarcinoma metastases and their indications for therapeutic response and prognosis.Therapeutic advances in medical oncology · 2025Review
- Gut microbiota-immunity cascade in hepatocellular carcinoma: mechanisms and therapeutic opportunities.Oncology reviews · 2025Review
- Microbes Saving Lives and Reducing Suffering.Microbial biotechnology · 2025Article
- Ursolic Acid Ameliorates Diabetic Nephropathy by Inhibiting JAK2/STAT3-Driven Ferroptosis: Mechanistic Insights from Network Pharmacology and Experimental Validation.Drug design, development and therapy · 2025Article
- Big lessons from the littleFrontiers in immunology · 2025Review
- Integrated molecular and microenvironmental drivers of drug resistance in gastrointestinal cancers: mechanisms, immunotherapy challenges, and precision strategies.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
As a Gram-negative anaerobic bacterium, Akkermansia muciniphila (AKK) participates in the immune response in many cancers. Our study focused on the factors and molecular mechanisms of AKK affecting immune escape in lung adenocarcinoma (LUAD). We cultured AKK bacteria, prepared AKK outer membrane protein Amuc_1100 and constructed a subcutaneous graft tumour mouse model. A549, NCI-H1395 cells and mice were respectively treated with inactivated AKK, Amuc_1100, Ruxolitinib (JAK inhibitor) and RO8191 (JAK activator). CD8
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.